Johnson & Johnson gains US approval for new daily psoriasis pill

statnews.com

Johnson & Johnson received U.S. approval for Icotyde, a daily pill for moderate to severe psoriasis, offering an alternative to injectable treatments. The new drug, Icotyde, is approved for patients aged 12 and older and aims to match the efficacy of existing injectable therapies without needles. This approval is expected to significantly impact the competitive psoriasis drug market, potentially expanding treatment options and generating substantial sales for J&J.


With a significance score of 5.5, this news ranks in the top 0.7% of today's 32120 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: